Enrollment Complete for Phase 3 Study
The enrollment for a United States Food and Drug Administration Phase 3 study is now complete for NexoBrid (MediWound Ltd, Yavne, Israel), with data expected in the final months of 2018. The DETECT study is a prospective, controlled, multinational, blinded Phase 3 study with 175 patients randomized to either treatment with the eschar removal agent, gel vehicle, or standard of care. This latest trial will evaluate the efficacy and safety of the eschar removal agent in hospitalized patients with severe burns by studying complete eschar removal; its secondary endpoints include reduction in surgical burden and blood loss as well as early eschar removal. The study is fully funded by the Biomedical and Advanced Research and Development Authority (Washington, DC).
Visit www.mediwound.com for more information.